Association between promoters polymorphisms of matrix metalloproteinases and risk of digestive cancers: a meta-analysis

详细信息    查看全文

• 作者：Xiaoying Li (1)
  Lianxi Qu (2)
  Yu Zhong (1)
  Yingjie Zhao (1)
  Hongyan Chen (1)
  Lu Daru (1)
  
• 关键词：Digestive cancers ; Matrix metalloproteinases ; Polymorphisms ; Meta ; analysis ; Susceptibility ; Risk
• 刊名：Journal of Cancer Research and Clinical Oncology
• 出版年：2013
• 出版时间：September 2013
• 年：2013
• 卷：139
• 期：9
• 页码：1433-1447
• 全文大小：421KB
• 参考文献：1. Agudo A, Bonet C, Travier N, Gonzalez CA, Vineis P, Bueno-de-Mesquita HB, Trichopoulos D, Boffetta P, Clavel-Chapelon F, Boutron-Ruault MC, Kaaks R, Lukanova A, Schutze M, Boeing H, Tjonneland A, Halkjaer J, Overvad K, Dahm CC, Quiros JR, Sanchez MJ, Larranaga N, Navarro C, Ardanaz E, Khaw KT, Wareham NJ, Key TJ, Allen NE, Trichopoulou A, Lagiou P, Palli D, Sieri S, Tumino R, Panico S, Boshuizen H, Buchner FL, Peeters PH, Borgquist S, Almquist M, Hallmans G, Johansson I, Gram IT, Lund E, Weiderpass E, Romieu I, Riboli E (2012) Impact of cigarette smoking on cancer risk in the European prospective investigation into cancer and nutrition study. J Clin Oncol 30(36):4550-557
  2. Ahmed MM, Mohammed SH (2011) Matrix metalloproteinases 2 and 9 in situ mRNA expression in colorectal tumors from Iraqi patients. Indian J Pathol Microbiol 54(1):7-4 CrossRef
  3. Alakus H, Afriani N, Warnecke-Eberz U, Bollschweiler E, Fetzner U, Drebber U, Metzger R, Holscher AH, Monig SP (2010) Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer. World J Surg 34(12):2853-859 CrossRef
  4. Back M, Ketelhuth DF, Agewall S (2010) Matrix metalloproteinases in atherothrombosis. Prog Cardiovasc Dis 52(5):410-28 CrossRef
  5. Basu P, Sen U, Tyagi N, Tyagi SC (2010) Blood flow interplays with elastin: collagen and MMP: TIMP ratios to maintain healthy vascular structure and function. Vasc Health Risk Manag 6:215-28
  6. Biondi ML, Turri O, Leviti S, Seminati R, Cecchini F, Bernini M, Ghilardi G, Guagnellini E (2000) MMP1 and MMP3 polymorphisms in promoter regions and cancer. Clin Chem 46(12):2023-024
  7. Bissell MJ, Kenny PA, Radisky DC (2005) Microenvironmental regulators of tissue structure and function also regulate tumor induction and progression: the role of extracellular matrix and its degrading enzymes. Cold Spring Harb Symp Quant Biol 70:343-56 CrossRef
  8. Bourboulia D, Stetler-Stevenson WG (2010) Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion. Semin Cancer Biol 20(3):161-68 CrossRef
  9. Bradbury PA, Zhai R, Hopkins J, Kulke MH, Heist RS, Singh S, Zhou W, Ma C, Xu W, Asomaning K, Ter-Minassian M, Wang Z, Su L, Christiani DC, Liu G (2009) Matrix metalloproteinase 1, 3 and 12 polymorphisms and esophageal adenocarcinoma risk and prognosis. Carcinogenesis 30(5):793-98 CrossRef
  10. Brew K, Dinakarpandian D, Nagase H (2000) Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 1477(1-):267-83 CrossRef
  11. Brinckerhoff CE, Rutter JL, Benbow U (2000) Interstitial collagenases as markers of tumor progression. Clin Cancer Res 6(12):4823-830
  12. Burn J, Mathers J, Bishop DT (2013) Genetics, inheritance and strategies for prevention in populations at high risk of colorectal cancer (CRC). Recent Results Cancer Res 191:157-83 CrossRef
  13. Chen XB, Chen GL, Liu JN, Yang JZ, Yu DK, Lin DX, Tan W (2009) Genetic polymorphisms in STK15 and MMP-2 associated susceptibility to esophageal cancer in Mongolian population. Zhonghua Yu Fang Yi Xue Za Zhi 43(7):559-64
  14. Chen PS, Shih YW, Huang HC, Cheng HW (2011) Diosgenin, a steroidal saponin, inhibits migration and invasion of human prostate cancer PC-3 cells by reducing matrix metalloproteinases expression. PLoS ONE 6(5):e20164 CrossRef
  15. Cheung WY, Zhai R, Bradbury P, Hopkins J, Kulke MH, Heist RS, Asomaning K, Ma C, Xu W, Wang Z, Hooshmand S, Su L, Christiani DC, Liu G (2012) Single nucleotide polymorphisms in the matrix metalloproteinase gene family and the frequency and duration of gastroesophageal reflux disease influence the risk of esophageal adenocarcinoma. Int J Cancer 131(11):2478-486 CrossRef
  16. de Lima JM, de Souza LG, da Silva ID, Forones NM (2009) E-cadherin and metalloproteinase-1 and -7 polymorphisms in colorectal cancer. Int J Biol Markers 24(2):99-06
  17. DerSimonian R, Kacker R (2007) Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 28(2):105-14 CrossRef
  18. Deryugina EI, Quigley JP (2006) Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25(1):9-4 CrossRef
  19. Dziki L, Przybylowska K, Majsterek I, Trzcinski R, Mik M, Sygut A (2011) A/G polymorphism of the MMP-7 gene promoter region in colorectal cancer. Pol Przegl Chir 83(11):622-26
  20. Elander N, Soderkvist P, Fransen K (2006) Matrix metalloproteinase (MMP) -1, -2, -3 and -9 promoter polymorphisms in colorectal cancer. Anticancer Res 26(1B):791-95
  21. Fang WL, Liang WB, He H, Zhu Y, Li SL, Gao LB, Zhang L (2010) Association of matrix metalloproteinases 1, 7, and 9 gene polymorphisms with genetic susceptibility to colorectal carcinoma in a Han Chinese population. DNA Cell Biol 29(11):657-61 CrossRef
  22. Gencer S, Cebeci A, Irmak-Yazicioglu MB (2011) Silencing of the MMP-3 gene by siRNA transfection in gastric cancer AGS cells. J Gastrointestin Liver Dis 20(1):19-6
  23. Ghilardi G, Biondi ML, Mangoni J, Leviti S, DeMonti M, Guagnellini E, Scorza R (2001) Matrix metalloproteinase-1 promoter polymorphism 1G/2G is correlated with colorectal cancer invasiveness. Clin Cancer Res 7(8):2344-346
  24. Gonzalez-Arriaga P, Pascual T, Garcia-Alvarez A, Fernandez-Somoano A, Lopez-Cima MF, Tardon A (2012) Genetic polymorphisms in MMP 2, 9 and 3 genes modify lung cancer risk and survival. BMC Cancer 12:121 CrossRef
  25. Grimm M, Lazariotou M, Kircher S, Stuermer L, Reiber C, Hofelmayr A, Gattenlohner S, Otto C, Germer CT, von Rahden BH (2010) MMP-1 is a (pre-)invasive factor in Barrett-associated esophageal adenocarcinomas and is associated with positive lymph node status. J Transl Med 8:99 CrossRef
  26. Haas SL, Ye W, Lohr JM (2012) Alcohol consumption and digestive tract cancer. Curr Opin Clin Nutr Metab Care 15(5):457-67 CrossRef
  27. Hinoda Y, Okayama N, Takano N, Fujimura K, Suehiro Y, Hamanaka Y, Hazama S, Kitamura Y, Kamatani N, Oka M (2002) Association of functional polymorphisms of matrix metalloproteinase (MMP)-1 and MMP-3 genes with colorectal cancer. Int J Cancer 102(5):526-29 CrossRef
  28. Itoh Y, Nagase H (2002) Matrix metalloproteinases in cancer. Essays Biochem 38:21-6
  29. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69-0 CrossRef
  30. Jin X, Kuang G, Wei LZ, Li Y, Wang R, Guo W, Wang N, Fang SM, Wen DG, Chen ZF, Zhang JH (2005) No association of the matrix metalloproteinase 1 promoter polymorphism with susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma in northern China. World J Gastroenterol 11(16):2385-389
  31. Kang MJ, Jung SA, Jung JM, Kim SE, Jung HK, Kim TH, Shim KN, Yi SY, Yoo K, Moon IH (2011) Associations between single nucleotide polymorphisms of MMP2, VEGF, and HIF1A genes and the risk of developing colorectal cancer. Anticancer Res 31(2):575-84
  32. Kemik O, Kemik AS, Sumer A, Dulger AC, Adas M, Begenik H, Hasirci I, Yilmaz O, Purisa S, Kisli E, Tuzun S, Kotan C (2011) Levels of matrix metalloproteinase-1 and tissue inhibitors of metalloproteinase-1 in gastric cancer. World J Gastroenterol 17(16):2109-112 CrossRef
  33. Kim J, Pyun JA, Cho SW, Lee K, Kwack K (2011a) Lymph node metastasis of gastric cancer is associated with the interaction between poly (ADP-ribose) polymerase 1 and matrix metallopeptidase 2. DNA Cell Biol 30(12):1011-017 CrossRef
  34. Kim JH, Pyun JA, Lee KJ, Cho SW, Kwack KB (2011b) Study on association between single nucleotide polymorphisms of MMP7, MMP8, MMP9 genes and development of gastric cancer and lymph node metastasis. Korean J Gastroenterol 58(5):245-51 CrossRef
  35. Kontou N, Psaltopoulou T, Soupos N, Polychronopoulos E, Xinopoulos D, Linos A, Panagiotakos D (2012) Alcohol consumption and colorectal cancer in a Mediterranean population: a case-control study. Dis Colon Rectum 55(6):703-10 CrossRef
  36. Kouhkan F, Motovali-Bashi M, Hojati Z (2008) The influence of interstitial collagenase-1 genotype polymorphism on colorectal cancer risk in Iranian population. Cancer Invest 26(8):836-42 CrossRef
  37. Kubben FJ, Sier CF, Meijer MJ, van den Berg M, van der Reijden JJ, Griffioen G, van de Velde CJ, Lamers CB, Verspaget HW (2006) Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer. Br J Cancer 95(6):744-51 CrossRef
  38. Lemaitre V, D’Armiento J (2006) Matrix metalloproteinases in development and disease. Birth Defects Res C Embryo Today 78(1):1-0 CrossRef
  39. Li Y, Sun DL, Duan YN, Zhang XJ, Wang N, Zhou RM, Chen ZF, Wang SJ (2010) Association of functional polymorphisms in MMPs genes with gastric cardia adenocarcinoma and esophageal squamous cell carcinoma in high incidence region of North China. Mol Biol Rep 37(1):197-05 CrossRef
  40. Lievre A, Milet J, Carayol J, Le Corre D, Milan C, Pariente A, Nalet B, Lafon J, Faivre J, Bonithon-Kopp C, Olschwang S, Bonaiti-Pellie C, Laurent-Puig P (2006) Genetic polymorphisms of MMP1, MMP3 and MMP7 gene promoter and risk of colorectal adenoma. BMC Cancer 6:270 CrossRef
  41. Lin SC, Chung MY, Huang JW, Shieh TM, Liu CJ, Chang KW (2004a) Correlation between functional genotypes in the matrix metalloproteinases-1 promoter and risk of oral squamous cell carcinomas. J Oral Pathol Med 33(6):323-26 CrossRef
  42. Lin SC, Lo SS, Liu CJ, Chung MY, Huang JW, Chang KW (2004b) Functional genotype in matrix metalloproteinases-2 promoter is a risk factor for oral carcinogenesis. J Oral Pathol Med 33(7):405-09 CrossRef
  43. Liu D, Duan W, Guo H, Xu X, Bai Y (2011a) Meta-analysis of associations between polymorphisms in the promoter regions of matrix metalloproteinases and the risk of colorectal cancer. Int J Colorectal Dis 26(9):1099-105 CrossRef
  44. Liu L, Wu C, Wang Y, Zhong R, Wang F, Zhang X, Duan S, Lou J, Yu D, Tan W, Yuan J, Wu T, Nie S, Miao X, Lin D (2011b) Association of candidate genetic variations with gastric cardia adenocarcinoma in Chinese population: a multiple interaction analysis. Carcinogenesis 32(3):336-42 CrossRef
  45. Lopez-Otin C, Palavalli LH, Samuels Y (2009) Protective roles of matrix metalloproteinases: from mouse models to human cancer. Cell Cycle 8(22):3657-662 CrossRef
  46. Lubin JH, Cook MB, Pandeya N, Vaughan TL, Abnet CC, Giffen C, Webb PM, Murray LJ, Casson AG, Risch HA, Ye W, Kamangar F, Bernstein L, Sharp L, Nyren O, Gammon MD, Corley DA, Wu AH, Brown LM, Chow WH, Ward MH, Freedman ND, Whiteman DC (2012) The importance of exposure rate on odds ratios by cigarette smoking and alcohol consumption for esophageal adenocarcinoma and squamous cell carcinoma in the Barrett’s Esophagus and Esophageal Adenocarcinoma Consortium. Cancer Epidemiol 36(3):306-16 CrossRef
  47. Malemud CJ (2006) Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci 11:1696-701 CrossRef
  48. Malik MA, Sharma KL, Zargar SA, Mittal B (2011a) Association of matrix metalloproteinase-7 (-181A?>?G) polymorphism with risk of esophageal squamous cell carcinoma in Kashmir valley. Saudi J Gastroenterol 17(5):301-06 CrossRef
  49. Malik MA, Zargar SA, Mittal B (2011b) Role of the metalloproteinase-7 (181A?>?G) polymorphism in gastric cancer susceptibility: a case control study in Kashmir valley. Asian Pac J Cancer Prev 12(1):73-6
  50. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22(4):719-48
  51. Matsumura S, Oue N, Kitadai Y, Chayama K, Yoshida K, Yamaguchi Y, Toge T, Imai K, Nakachi K, Yasui W (2004) A single nucleotide polymorphism in the MMP-1 promoter is correlated with histological differentiation of gastric cancer. J Cancer Res Clin Oncol 130(5):259-65 CrossRef
  52. Matsumura S, Oue N, Nakayama H, Kitadai Y, Yoshida K, Yamaguchi Y, Imai K, Nakachi K, Matsusaki K, Chayama K, Yasui W (2005) A single nucleotide polymorphism in the MMP-9 promoter affects tumor progression and invasive phenotype of gastric cancer. J Cancer Res Clin Oncol 131(1):19-5 CrossRef
  53. McColgan P, Sharma P (2009) Polymorphisms of matrix metalloproteinases 1, 2, 3 and 9 and susceptibility to lung, breast and colorectal cancer in over 30,000 subjects. Int J Cancer 125(6):1473-478 CrossRef
  54. Miao X, Yu C, Tan W, Xiong P, Liang G, Lu W, Lin D (2003) A functional polymorphism in the matrix metalloproteinase-2 gene promoter (-1306C/T) is associated with risk of development but not metastasis of gastric cardia adenocarcinoma. Cancer Res 63(14):3987-990
  55. Mroczko B, Lukaszewicz-Zajac M, Gryko M, Kedra B, Szmitkowski M (2011) Clinical significance of serum levels of matrix metalloproteinase 2 (MMP-2) and its tissue inhibitor (TIMP-2) in gastric cancer. Folia Histochem Cytobiol 49(1):125-31
  56. Nishioka Y, Sagae S, Nishikawa A, Ishioka S, Kudo R (2003) A relationship between matrix metalloproteinase-1 (MMP-1) promoter polymorphism and cervical cancer progression. Cancer Lett 200(1):49-5 CrossRef
  57. Nishizawa R, Nagata M, Noman AA, Kitamura N, Fujita H, Hoshina H, Kubota T, Itagaki M, Shingaki S, Ohnishi M, Kurita H, Katsura K, Saito C, Yoshie H, Takagi R (2007) The 2G allele of promoter region of matrix metalloproteinase-1 as an essential pre-condition for the early onset of oral squamous cell carcinoma. BMC Cancer 7:187 CrossRef
  58. Oc P, Leksrisakul P, Sangruchi S (2006) A functional polymorphism in the matrix metalloproteinase-1 gene promoter is associated with susceptibility and aggressiveness of head and neck cancer. Int J Cancer 118(10):2548-553 CrossRef
  59. Ohtani H, Maeda N, Murawaki Y (2009) Functional polymorphisms in the promoter regions of matrix metalloproteinase-2,-3,-7,-9 and TNF-alpha genes, and the risk of colorectal neoplasm in Japanese. Yonago Acta Medica 52(1):47-6
  60. Park KS, Kim SJ, Kim KH, Kim JC (2011) Clinical characteristics of TIMP2, MMP2, and MMP9 gene polymorphisms in colorectal cancer. J Gastroenterol Hepatol 26(2):391-97 CrossRef
  61. Pellegrini ML, Argibay P, Gomez DE (2011) Genetics and epigenetics of colorectal cancer. Acta Gastroenterol Latinoam 41(3):247-61
  62. Price SJ, Greaves DR, Watkins H (2001) Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem 276(10):7549-558 CrossRef
  63. Roy R, Yang J, Moses MA (2009) Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 27(31):5287-297 CrossRef
  64. Rutter JL, Mitchell TI, Buttice G, Meyers J, Gusella JF, Ozelius LJ, Brinckerhoff CE (1998) A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res 58(23):5321-325
  65. Sfar S, Saad H, Mosbah F, Gabbouj S, Chouchane L (2007) TSP1 and MMP9 genetic variants in sporadic prostate cancer. Cancer Genet Cytogenet 172(1):38-4 CrossRef
  66. Srivastava P, Kapoor R, Mittal RD (2009) Influence of matrix metalloproteinase gene polymorphisms in healthy North Indians compared to variations in other ethnic groups worldwide. Asian Pac J Cancer Prev 10(6):1127-130
  67. Srivastava P, Gangwar R, Kapoor R, Mittal RD (2010) Bladder cancer risk associated with genotypic polymorphism of the matrix metalloproteinase-1 and 7 in North Indian population. Dis Markers 29(1):37-6 CrossRef
  68. Strohle A, Maike W, Hahn A (2007) Nutrition and colorectal cancer. Med Monatsschr Pharm 30(1):25-2
  69. Sugimoto M, Furuta T, Kodaira C, Nishino M, Yamade M, Ikuma M, Sugimura H, Hishida A (2008) Polymorphisms of matrix metalloproteinase-7 and chymase are associated with susceptibility to and progression of gastric cancer in Japan. J Gastroenterol 43(10):751-61 CrossRef
  70. Surlin V, Ioana M, Plesea IE (2011) Genetic patterns of metalloproteinases and their tissular inhibitors - clinicopathologic and prognostic significance in colorectal cancer. Rom J Morphol Embryol 52(1 Suppl):231-36
  71. Tang FY, Pai MH, Wang XD (2011) Consumption of lycopene inhibits the growth and progression of colon cancer in a mouse xenograft model. J Agric Food Chem 59(16):9011-021 CrossRef
  72. Tower GB, Coon CI, Belguise K, Chalbos D, Brinckerhoff CE (2003) Fra-1 targets the AP-1 site/2G single nucleotide polymorphism (ETS site) in the MMP-1 promoter. Eur J Biochem 270(20):4216-225 CrossRef
  73. Tu HF, Wu CH, Kao SY, Liu CJ, Liu TY, Lui MT (2007) Functional -1562 C-to-T polymorphism in matrix metalloproteinase-9 (MMP-9) promoter is associated with the risk for oral squamous cell carcinoma in younger male areca users. J Oral Pathol Med 36(7):409-14 CrossRef
  74. Vairaktaris E, Serefoglou Z, Avgoustidis D, Yapijakis C, Critselis E, Vylliotis A, Spyridonidou S, Derka S, Vassiliou S, Nkenke E, Patsouris E (2009) Gene polymorphisms related to angiogenesis, inflammation and thrombosis that influence risk for oral cancer. Oral Oncol 45(3):247-53 CrossRef
  75. Vogelaar IP, van der Post RS, Bisseling TM, van Krieken JH, Ligtenberg MJ, Hoogerbrugge N (2012) Familial gastric cancer: detection of a hereditary cause helps to understand its etiology. Hered Cancer Clin Pract 10(1):18 CrossRef
  76. Woo M, Park K, Nam J, Kim JC (2007) Clinical implications of matrix metalloproteinase-1, -3, -7, -9, -12, and plasminogen activator inhibitor-1 gene polymorphisms in colorectal cancer. J Gastroenterol Hepatol 22(7):1064-070 CrossRef
  77. Wu CY, Wu MS, Chen YJ, Chen CJ, Chen HP, Shun CT, Chen GH, Huang SP, Lin JT (2007) Clinicopathological significance of MMP-2 and TIMP-2 genotypes in gastric cancer. Eur J Cancer 43(4):799-08 CrossRef
  78. Wyatt CA, Coon CI, Gibson JJ, Brinckerhoff CE (2002) Potential for the 2G single nucleotide polymorphism in the promoter of matrix metalloproteinase to enhance gene expression in normal stromal cells. Cancer Res 62(24):7200-202
  79. Xing LL, Wang ZN, Jiang L, Zhang Y, Xu YY, Li J, Luo Y, Zhang X (2007) Matrix metalloproteinase-9-1562C?>?T polymorphism may increase the risk of lymphatic metastasis of colorectal cancer. World J Gastroenterol 13(34):4626-629
  80. Xu E, Lai M, Lu B, Xing X, Huang Q (2006a) No association between the polymorphisms in matrix metalloproteinase-1 and matrix metalloproteinase-3 promoter regions and colorectal cancer in Chinese. Dis Colon Rectum 49(9):1439-444 CrossRef
  81. Xu EP, Huang Q, Lu BJ, Xing XM, Lai MD (2006b) The correlation between polymorphisms of matrix metalloproteinase-2 and -9 genes and colorectal cancer of Chinese patients. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 23(1):78-1
  82. Yan C, Boyd DD (2007) Regulation of matrix metalloproteinase gene expression. J Cell Physiol 211(1):19-6 CrossRef
  83. Ye S (2000) Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol 19(7):623-29 CrossRef
  84. Yu C, Zhou Y, Miao X, Xiong P, Tan W, Lin D (2004) Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res 64(20):7622-628 CrossRef
  85. Zhang B, Henney A, Eriksson P, Hamsten A, Watkins H, Ye S (1999) Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12.2-13.1. Hum Genet 105(5):418-23 CrossRef
  86. Zhang J, Jin X, Fang S, Li Y, Wang R, Guo W, Wang N, Wang Y, Wen D, Wei L, Kuang G, Dong Z (2004a) The functional SNP in the matrix metalloproteinase-3 promoter modifies susceptibility and lymphatic metastasis in esophageal squamous cell carcinoma but not in gastric cardiac adenocarcinoma. Carcinogenesis 25(12):2519-524 CrossRef
  87. Zhang XM, Miao XP, Xiong P, Yu CY, Tan W, Qu SN, Sun T, Zhou YF, Lin DX (2004b) Association of functional polymorphisms in matrix metalloproteinase-2 (MMP-2) and MMP-9 genes with risk of gastric cancer in a Chinese population. Ai Zheng 23(11):1233-237
  88. Zhang J, Jin X, Fang S, Wang R, Li Y, Wang N, Guo W, Wang Y, Wen D, Wei L, Dong Z, Kuang G (2005) The functional polymorphism in the matrix metalloproteinase-7 promoter increases susceptibility to esophageal squamous cell carcinoma, gastric cardiac adenocarcinoma and non-small cell lung carcinoma. Carcinogenesis 26(10):1748-753 CrossRef
  89. Zhang WQ, Lin H, Zhou YA, Wang YJ, Cheng QS (2006) Association of MMP1 -1607(1G?>?2G)single nucleotide polymorphism with susceptibility to lung cancer in Northwestern Chinese population of Han nationality. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 23(3):313-15
  90. Zhang LF, Mi YY, Cao Q, Wang W, Qin C, Wei JF, Zhou YJ, Li YF, Tang M, Liu WM, Zhang W, Zou JG (2012) Update analysis of studies on the MMP-9 -1562 C?>?T polymorphism and cancer risk. Mol Biol Rep 39(4):3435-441 CrossRef
  91. Zhou J, Brinckerhoff C, Lubert S, Yang K, Saini J, Hooke J, Mural R, Shriver C, Somiari S (2011a) Analysis of matrix metalloproteinase-1 gene polymorphisms and expression in benign and malignant breast tumors. Cancer Invest 29(9):599-07 CrossRef
  92. Zhou JH, Zhang B, Kernstine KH, Zhong L (2011b) Autoantibodies against MMP-7 as a novel diagnostic biomarker in esophageal squamous cell carcinoma. World J Gastroenterol 17(10):1373-378 CrossRef
  
• 作者单位：Xiaoying Li (1)
  Lianxi Qu (2)
  Yu Zhong (1)
  Yingjie Zhao (1)
  Hongyan Chen (1)
  Lu Daru (1)
  
  1. State Key Laboratory of Genetic Engineering, Fudan-VARI Genetic Epidemiology Center and MOE Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, 200433, People’s Republic of China
  2. Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, People’s Republic of China
  

文摘

Purpose A variety of studies have been performed to elucidate the polymorphisms in promoter regions of matrix metalloproteinases (MMPs) associated with the risk of digestive cancers, and yet, results remain conflicting and heterogeneous. Thus, we undertook a systematic meta-analysis to determine the genetic susceptibility of MMPs to digestive cancers. Methods A computerized literature search was conducted in databases of PubMed, Embase, and ISI Web of Knowledge till October 2012 for any MMP genetic association study in oral squamous, gastric, esophageal, and colorectal carcinomas. Odds ratios (OR) and 95?% confidence interval (CI) were estimated for each gene under dominant and recessive models, and the heterogeneity between studies was assessed using Q test and I 2 value. Overall and subgroup analysis according to anatomical sites and ethnicity was carried out. Statistical analysis was performed with Review Manager 5.0. Results A total of 40 eligible publications with 68 comparisons were included in this study. For MMP1 nt-1607, individuals with 2G state could increase risk of digestive cancers in total analysis (dominant: OR?=?1.31, 95?% CI?=?1.16-.48, P?<?0.00001; recessive: OR?=?1.29, 95?% CI?=?1.11-.50, P?=?0.0009). In the subgroup of tumor sites, significant associations were also observed in esophageal cancer and colorectal cancer under both genetic models. For MMP2 nt-1306, CT or TT carriers performed significant protection against digestive cancer in the dominant model (OR?=?0.69, 95?% CI?=?0.55-.85, P?=?0.0007) of the overall. In the subgroup analysis, significant association was found in esophageal cancer, with borderline effects in gastric cancer and oral squamous cell carcinoma. For MMP7 ?81 A/G, significant association was observed under two genetic models in the overall (dominant: OR?=?1.26, 95?% CI?=?1.10-.43, P?=?0.0009; recessive: OR?=?1.33, 95?% CI?=?1.11-.60, P?=?0.002) and in the individual cancer subgroup of esophageal cancer and gastric cancer. For MMP9 ?,562 C/T, a borderline effect was found with digestive cancers in the total and stratified analysis of the colorectal cancer under dominant model. No association was observed in either the overall or subgroup analysis for MMP3 ?,171 5A/6A. Conclusions Our meta-analysis demonstrated the fact that polymorphisms in promoter regions of MMP genes might be related to the susceptibility of digestive cancers, with cancer development for MMP1 and MMP7, and a protection against cancer for MMP2 and MMP9. Further evidences with adequate sample sizes need to be conducted.